Masking MALT1: the paracaspase's potential for cancer therapy

A key feature of aggressive B cell lymphomas is constitutive NF-κB activation, which requires signals from the CARD11–BCL-10–MALT1 (CMB) complex. The unique enzymatic activity of MALT1 degrades one of its binding partners, BCL-10, as well as the NF-κB inhibitor A20. New data shows that targeting MAL...

Descripción completa

Detalles Bibliográficos
Autores principales: Vucic, Domagoj, Dixit, Vishva M.
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2009
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768848/
https://www.ncbi.nlm.nih.gov/pubmed/19841088
http://dx.doi.org/10.1084/jem.20092160
_version_ 1782173521402658816
author Vucic, Domagoj
Dixit, Vishva M.
author_facet Vucic, Domagoj
Dixit, Vishva M.
author_sort Vucic, Domagoj
collection PubMed
description A key feature of aggressive B cell lymphomas is constitutive NF-κB activation, which requires signals from the CARD11–BCL-10–MALT1 (CMB) complex. The unique enzymatic activity of MALT1 degrades one of its binding partners, BCL-10, as well as the NF-κB inhibitor A20. New data shows that targeting MALT1 protease activity may be a promising therapeutic strategy for treating aggressive B cell lymphomas.
format Text
id pubmed-2768848
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-27688482010-04-26 Masking MALT1: the paracaspase's potential for cancer therapy Vucic, Domagoj Dixit, Vishva M. J Exp Med Commentary A key feature of aggressive B cell lymphomas is constitutive NF-κB activation, which requires signals from the CARD11–BCL-10–MALT1 (CMB) complex. The unique enzymatic activity of MALT1 degrades one of its binding partners, BCL-10, as well as the NF-κB inhibitor A20. New data shows that targeting MALT1 protease activity may be a promising therapeutic strategy for treating aggressive B cell lymphomas. The Rockefeller University Press 2009-10-26 /pmc/articles/PMC2768848/ /pubmed/19841088 http://dx.doi.org/10.1084/jem.20092160 Text en © 2009 Vucic and Dixit This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
spellingShingle Commentary
Vucic, Domagoj
Dixit, Vishva M.
Masking MALT1: the paracaspase's potential for cancer therapy
title Masking MALT1: the paracaspase's potential for cancer therapy
title_full Masking MALT1: the paracaspase's potential for cancer therapy
title_fullStr Masking MALT1: the paracaspase's potential for cancer therapy
title_full_unstemmed Masking MALT1: the paracaspase's potential for cancer therapy
title_short Masking MALT1: the paracaspase's potential for cancer therapy
title_sort masking malt1: the paracaspase's potential for cancer therapy
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768848/
https://www.ncbi.nlm.nih.gov/pubmed/19841088
http://dx.doi.org/10.1084/jem.20092160
work_keys_str_mv AT vucicdomagoj maskingmalt1theparacaspasespotentialforcancertherapy
AT dixitvishvam maskingmalt1theparacaspasespotentialforcancertherapy

Ejemplares similares